Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

Fig. 2

Co-administration of SAHA and veliparib synergistically increased PCa killing. PCa and non-malignant prostate epithelial cells were treated with increased doses of SAHA or veliparib alone or in combination at a constant ratio of 1:20 for 3 days. Representative crystal violet-stained cell images are shown (left). The cells were lysed with 1% SDS, and cell viability was measured by spectrometer as OD570 nm. Graph represents the mean cell viability ± SD of 3 independent experiments.* p < 0.05;**p < 0.01(co-treatment vs. SAHA or veliparib alone). a LNCaP. b C4–2. c VCaP. d CWR22Rv1. e PC-3. f DU145. g RWPE-1

Back to article page